Market Overview

Mylan Pharma Wins Final FDA Approval for ANDA for Phenytoin Chewable Tablets, 50 mg

Related MYL
CNBC's Stock Pops & Drops From November 26
Teva Beats Q3 Earnings Expectations, Updates Outlook
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)
Related PFE
CNBC'S Catherine Boyle Doesn't Think A Pfizer/AstraZeneca Deal Will Happen Soon
When There's A Pullback On A Bull, Look At These Leading ETFs
Divided Government Won't Halt Street's Run (Fox Business)

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Phenytoin Chewable Tablets USP, 50 mg. This product is the generic version of Pfizer's Dilantin® Chewable Tablets, which are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments.

Posted-In: News FDA

 

Related Articles (MYL + PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters